Skip to content
Medical Health Aged Care, Science

Key to more effective vaccines revealed

Centenary Institute 2 mins read
Dr Erica Stewart

Researchers from the Centenary Institute and the University of Sydney have made a major discovery in vaccine science, gaining new insights into delta inulin as a crucial vaccine component. Their findings offer a promising pathway for advancing the next generation of vaccines.

 

Delta inulin, an adjuvant, has long been recognised for its ability to boost immune responses against a range of infectious diseases such as COVID-19, influenza, tuberculosis and hepatitis B. Adjuvants are substances added to vaccines to elicit stronger and longer-lasting immune responses, thereby improving vaccine effectiveness.

 

Despite its established role in vaccines, the precise mechanisms underlying delta inulin’s action had remained elusive.

 

Now, in a ground-breaking study published in the prestigious journal Immunology & Cell Biology, researchers have discovered a pivotal aspect of the adjuvant’s functionality.

 

Using a diverse range of techniques, the study identified a protein known as Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-Integrin (DC-SIGN) as a receptor for delta inulin.

 

Dr Erica Stewart, the lead author of the study and a researcher at the Centenary Institute’s Centre for Infection & Immunity and the University of Sydney Infectious Diseases Institute, said that DC-SIGN is a protein found on the surface of certain immune cells called dendritic cells.

 

"DC-SIGN acts like a lock on cell surfaces and delta inulin functions as the key that fits into this lock, binding them together. This study shows that when we vaccinate with delta inulin, our cells use DC-SIGN to detect the vaccine, which then helps activate and boost the body’s immune response."

 

Dr Stewart says the study’s findings carry important implications for future vaccine development.

 

“This study not only offers us improved understanding of the intricate mechanisms governing vaccine immune responses to delta inulin but also opens up new avenues for the development of next-generation vaccines,” Dr Stewart said.

 

“With this new insight into delta inulin’s mode of action, researchers can now explore the creation of new vaccines that work hand-in-hand with delta inulin, offering even greater protection against existing and emerging infectious diseases.”

 

“This breakthrough is like finding a crucial piece of the puzzle that can make our vaccines smarter, leading to better health and safety for people worldwide,” she said.

 

[ENDS]

 


Key Facts:

Publication:

Dendritic cell–specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a cellular receptor for delta inulin adjuvant.

https://onlinelibrary.wiley.com/doi/10.1111/imcb.12774


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

For more information about the Centenary Institute, visit centenary.org.au

 

About the University of Sydney, Australia

As Australia’s first university – founded in 1850 – the University of Sydney has a proud history of global leadership in education and research and inspiring people from all backgrounds to contribute to positive real-world change. We’re a world-renowned teaching and research institution – our research combines the expertise and talents of scholars from many disciplines.

Learn more.


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: t.crawshaw@centenary.org.au

Media

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.